Serum from COVID-19 patients promotes endothelial cell dysfunction through protease-activated receptor 2
Description
CONCLUSION: Our findings provide the rationale for further studies to evaluate whether targeting PAR-2 may be a clinically effective strategy to counteract endothelial dysfunction in COVID-19.
